Allergan migraine drug succeeds in second late-stage trial
NEW YORK (Reuters) - Allergan Plc on Friday announced positive results from a second Phase III trial for the 50 milligram dose of its drug for acute migraine, reproducing results from the previous trial.
from Reuters: Health News https://reut.rs/2JAaAcl
http://bit.ly/2zwRqiM
April 27, 2018
|
Labels:
health,
Reuters: Health News
|
This entry was posted on April 27, 2018
and is filed under
health
,
Reuters: Health News
.
You can follow any responses to this entry through
the RSS 2.0 feed.
or trackback from your own site.